And here’s the kicker-it’s not even expensive. Not anymore. Down nearly 25% from its 2023 highs? What is this, a clearance sale for one of the biggest consumer staples companies in the world? It’s practically screaming, “Buy me!” But does anyone listen? Of course not. Because apparently, if something isn’t complicated enough to require a PhD in blockchain theory, it’s just not worth paying attention to.
Enter Archer Aviation (ACHR), the company building electric vertical takeoff-and-landing (eVTOL) aircraft that promise to whisk you above gridlocked cities. FAA approval is allegedly “just around the corner,” though bureaucracies have a habit of turning “just around the corner” into a three-season Netflix series. These aren’t your grandpa’s noisy helicopters-they’re quieter, nimbler, and theoretically less likely to crash into your rooftop mailbox.
American Express has always been the guy who shows up to the party with a bottle of wine and a side of entitlement. They cater to the elite, offering rewards that feel less like perks and more like a tax on your wallet. It’s like they’re saying, “We’ll take your money, and then we’ll pretend we’re doing you a favor.” Despite having fewer users than Visa, they somehow make twice the cash. Because of course they do. The rich are just better at spending, apparently.
High-yield funds are meant to be the gray horses of investing-unflashy, dependable, and occasionally overlooked. Yet here it is, outpacing the frenzy of speculative ventures. One might suppose this is a trick of the light, a mirage born of temporary fortune. But the numbers persist, stubborn as the tides. Why, then, do so many portfolios remain empty of this quiet abundance?
Picture, if you will, a man standing before an audience of bespectacled financiers, his voice dripping with the honeyed assurance of a merchant selling golden eggs. This man is Matthew Klein, CEO of PTC Therapeutics, who spoke not of wars or revolutions but of something far more insidious: phenylketonuria, or PKU. Imagine a condition so cruel that it forces its victims into a lifetime of dietary asceticism, banishing them from the simple joys of chocolate cake and roasted meats. And lo, here comes Sephience, their savior-an oral therapy approved both in the U.S. and Europe, capable of lowering the accursed levels of phenylalanine that build up in these poor souls.
And yet, there exists within this tempestuous narrative a singular ray of hope, faint but unyielding-a green flag fluttering against an ashen sky. This beacon is not born of speculative dreams or fleeting trends; it is rooted in something far more enduring: Target’s dividend.
Year-to-date, shares are down 5% (the S&P 500 laughs from +9%). Yet here we are, dissecting orforglipron, an oral GLP-1 drug that’s somehow both underwhelming and overhyped. If this were a first date, it’d be the guy who shows up late, spills wine on your shirt, then insists he’s “basically a sommelier.”
In the second quarter of 2025, he liquidated stakes in Broadcom (AVGO) and Meta Platforms (META), appending 755,000 shares of Taiwan Semiconductor Manufacturing (TSM) to his portfolio-a 279.6% increase. The transaction reads less like a trade and more like a bureaucratic appeal: a desperate attempt to align with a system that demands both obedience and absurdity.
Investors, ever the fickle lot, have fled the scene, their pockets lighter than a beggar’s satchel. The reason? A slowdown in Figma’s growth rate, a phenomenon as alarming as a goblin discovering it’s been eating the same meal for a week.
Let’s dissect this like a passive-aggressive thank-you note. Why might SentinelOne be the growth stock equivalent of a perfectly ripe avocado? Buckle up, because here’s where things get interesting.